Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Insulin Resistance-Pipeline Review, H1 2015

Insulin Resistance-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Insulin Resistance-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Insulin Resistance-Pipeline Review, H1 2015', provides an overview of the Insulin Resistance's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Insulin Resistance

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Insulin Resistance and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Insulin Resistance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Insulin Resistance pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Insulin Resistance

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Insulin Resistance Overview 8

Therapeutics Development 9

Pipeline Products for Insulin Resistance-Overview 9

Pipeline Products for Insulin Resistance-Comparative Analysis 10

Insulin Resistance-Therapeutics under Development by Companies 11

Insulin Resistance-Therapeutics under Investigation by Universities/Institutes 13

Insulin Resistance-Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Insulin Resistance-Products under Development by Companies 16

Insulin Resistance-Products under Investigation by Universities/Institutes 17

Insulin Resistance-Companies Involved in Therapeutics Development 18

AUS Bio Limited 18

Genfit SA 19

GlaxoSmithKline plc 20

Hadasit Medical Research Services & Development Ltd 21

Mertiva AB 22

Mochida Pharmaceutical Co., Ltd. 23

Novartis AG 24

Prometheon Pharma, LLC 25

Sanofi 26

Thetis Pharmaceuticals LLC 27

Insulin Resistance-Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

6860766-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

BVS-857-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Drugs to Inhibit TRIP-Br2 for Metabolic Disorders-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Englerin A-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

GFT-505-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

MD-960-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

PEG-Catalase-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Peptide for Obesity and Insulin Resistance-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

SAR-088-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

SERX-1-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Small Molecule for Hypertension and Insulin Resistance-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Small Molecule to Target AMPD2 for Hypertension and Metabolic Disorders-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

TP-113-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Insulin Resistance-Recent Pipeline Updates 60

Insulin Resistance-Dormant Projects 66

Insulin Resistance-Product Development Milestones 67

Featured News & Press Releases 67

Oct 19, 2011: Genfit Announces Hospital-Based Clinical Study Demonstrates Action Of GFT505 On Liver 67

Appendix 68

Methodology 68

Coverage 68

Secondary Research 68

Primary Research 68

Expert Panel Validation 68

Contact Us 69

Disclaimer 69

List of Tables

Number of Products under Development for Insulin Resistance, H1 2015 9

Number of Products under Development for Insulin Resistance-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Insulin Resistance-Pipeline by AUS Bio Limited, H1 2015 18

Insulin Resistance-Pipeline by Genfit SA, H1 2015 19

Insulin Resistance-Pipeline by GlaxoSmithKline plc, H1 2015 20

Insulin Resistance-Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015 21

Insulin Resistance-Pipeline by Mertiva AB, H1 2015 22

Insulin Resistance-Pipeline by Mochida Pharmaceutical Co., Ltd., H1 2015 23

Insulin Resistance-Pipeline by Novartis AG, H1 2015 24

Insulin Resistance-Pipeline by Prometheon Pharma, LLC, H1 2015 25

Insulin Resistance-Pipeline by Sanofi, H1 2015 26

Insulin Resistance-Pipeline by Thetis Pharmaceuticals LLC, H1 2015 27

Assessment by Monotherapy Products, H1 2015 28

Number of Products by Stage and Target, H1 2015 30

Number of Products by Stage and Mechanism of Action, H1 2015 32

Number of Products by Stage and Route of Administration, H1 2015 34

Number of Products by Stage and Molecule Type, H1 2015 36

Insulin Resistance Therapeutics-Recent Pipeline Updates, H1 2015 60

Insulin Resistance-Dormant Projects, H1 2015 66

List of Figures

Number of Products under Development for Insulin Resistance, H1 2015 9

Number of Products under Development for Insulin Resistance-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 28

Number of Products by Top 10 Targets, H1 2015 29

Number of Products by Stage and Top 10 Targets, H1 2015 29

Number of Products by Top 10 Mechanism of Actions, H1 2015 31

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 31

Number of Products by Top 10 Routes of Administration, H1 2015 33

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 34

Number of Products by Top 10 Molecule Types, H1 2015 35

Number of Products by Stage and Top 10 Molecule Types, H1 2015 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AUS Bio Limited

Genfit SA

GlaxoSmithKline plc

Hadasit Medical Research Services & Development Ltd

Mertiva AB

Mochida Pharmaceutical Co., Ltd.

Novartis AG

Prometheon Pharma, LLC

Sanofi

Thetis Pharmaceuticals LLC

Insulin Resistance Therapeutic Products under Development, Key Players in Insulin Resistance Therapeutics, Insulin Resistance Pipeline Overview, Insulin Resistance Pipeline, Insulin Resistance Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com